RecruitingNCT07215923
Official study titleA First in Human, Double-Blind, Placebo-Controlled, Randomized Evaluation of Single Ascending Doses of ATI-1013, a Human Monoclonal Antibody to Nicotine in Healthy Smokers
In Overland ParkAddictionPlacebo researchAges 23–59
- Countries
- United States
- Sponsor
- Antidote Therapeutics, Inc
RecruitingNCT05913752
About this title
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
Read the official source — NCT05913752Official study titleA Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects With Alcohol Use Disorder (AUD)
Multiple locations, including New HavenAddictionPlacebo comparisonAges 18–60
- Countries
- United States, Israel
- Sponsor
- Clearmind Medicine Inc.
RecruitingNCT06925867
About this title
A Frequency-Modulated Music Intervention to Enhance Cognitive Processing Therapy (CPT) for PTSD
Read the official source — NCT06925867Official study titleA Frequency-Modulated Music Intervention to Enhance Cognitive Processing Therapy (CPT) for PTSD
Multiple locations, including ColumbusPTSDBehavioural studyAges 18+
- Countries
- United States
- Sponsor
- Ohio State University
RecruitingISRCTN69012026
In United KingdomAnxietyResearch studyAges 18–100
- Countries
- United Kingdom
- Sponsor
- Devon Partnership NHS Trust
RecruitingNCT06990191
About this title
A Hybrid 1 Effectiveness-Implementation Trial of Partner-Assisted Prolonged Exposure for PTSD
Read the official source — NCT06990191Official study titleA Hybrid 1 Effectiveness-Implementation Trial of Partner-Assisted Prolonged Exposure for PTSD
In San DiegoPTSDBehavioural studyAges 18+
- Countries
- United States
- Sponsor
- United States Department of Defense
RecruitingACTRN12624000195550
Official study titleA hybrid randomised controlled feasibility pilot trial of a self-management intervention “My Personal REcovery Plan” (MyPREP) for people with long term mental health conditions: The MyPREP Trial
In AustraliaPersonality disorders, PTSD, ...Interventional studyAges 18+
- Countries
- Australia
- Sponsor
- The University of Sydney
RecruitingNCT07348666
Official study titleBRITE 2.0: A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents (ViraSafe RCT (SBIR Phase 2))
In PittsburghSuicidalityBehavioural studyAges 13–24
- Countries
- United States
- Sponsor
- Ksana Health
RecruitingNCT06597695
About this title
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
Read the official source — NCT06597695Official study titleA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
In ChelseaDepressionMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Juliana Zambrano, MD, MPH
RecruitingNCT07206212
Official study titleEfficacy and Cost-effectiveness of a Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder: A Randomized Controlled Trial
Original registry wording; source language not specified.
In HuddingeOCDResearch studyAges 18–100
- Countries
- Sweden
- Sponsor
- Psychiatry Southwest [Psykiatri Sydväst], Stockholm Healthcare Services [Stockholms läns sjukvårdsområde (SLSO)], Region Stockholm
RecruitingISRCTN94481360
In United KingdomMental healthResearch studyAges 18–120
- Countries
- United Kingdom
- Sponsor
- Lancashire and South Cumbria NHS Foundation Trust
RecruitingNCT07225712
What is this study about?Researchers are studying SEP-363856, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
In FukuokaSchizophreniaMedication studyAges 18+
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
RecruitingNCT07459647
What is this study about?Researchers are studying ML-007C-MA, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- MapLight Therapeutics